JP2006524668A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524668A5 JP2006524668A5 JP2006505807A JP2006505807A JP2006524668A5 JP 2006524668 A5 JP2006524668 A5 JP 2006524668A5 JP 2006505807 A JP2006505807 A JP 2006505807A JP 2006505807 A JP2006505807 A JP 2006505807A JP 2006524668 A5 JP2006524668 A5 JP 2006524668A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- groups
- group
- optionally substituted
- ny1y2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims 72
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 35
- 150000003839 salts Chemical class 0.000 claims 35
- 125000003545 alkoxy group Chemical group 0.000 claims 32
- -1 arylcarboxy Chemical group 0.000 claims 27
- 125000005843 halogen group Chemical group 0.000 claims 26
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 125000003342 alkenyl group Chemical group 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 150000002431 hydrogen Chemical group 0.000 claims 16
- 150000007529 inorganic bases Chemical class 0.000 claims 16
- 150000007522 mineralic acids Chemical class 0.000 claims 16
- 150000007524 organic acids Chemical class 0.000 claims 16
- 235000005985 organic acids Nutrition 0.000 claims 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 14
- 150000007530 organic bases Chemical class 0.000 claims 14
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 13
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 13
- 125000003226 pyrazolyl group Chemical group 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 11
- 125000004076 pyridyl group Chemical group 0.000 claims 11
- 239000004480 active ingredient Substances 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 102000001253 Protein Kinase Human genes 0.000 claims 8
- 108060006633 protein kinase Proteins 0.000 claims 8
- 125000001544 thienyl group Chemical group 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 7
- 125000004193 piperazinyl group Chemical group 0.000 claims 7
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 6
- 125000003884 phenylalkyl group Chemical group 0.000 claims 6
- 125000005936 piperidyl group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- 125000004104 aryloxy group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 5
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 5
- 125000002755 pyrazolinyl group Chemical group 0.000 claims 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical group C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 claims 4
- 125000005359 phenoxyalkyl group Chemical group 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 210000003584 mesangial cell Anatomy 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000002071 phenylalkoxy group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- ROBLKZZJHHQLLF-UHFFFAOYSA-N 2-[3-[(3-fluorophenyl)methoxy]-1H-pyrazol-5-yl]-1H-indole Chemical compound FC1=CC=CC(COC=2NN=C(C=2)C=2NC3=CC=CC=C3C=2)=C1 ROBLKZZJHHQLLF-UHFFFAOYSA-N 0.000 claims 1
- IVNMWVVOFVPHPL-UHFFFAOYSA-N 3-[[5-(1H-indol-2-yl)-1H-pyrazol-3-yl]oxymethyl]phenol Chemical compound OC1=CC=CC(COC=2NN=C(C=2)C=2NC3=CC=CC=C3C=2)=C1 IVNMWVVOFVPHPL-UHFFFAOYSA-N 0.000 claims 1
- JUCQIXUOLHWYIO-UHFFFAOYSA-N 6h-[1,3]dioxolo[4,5-e]benzimidazole Chemical group C1=C2N=CNC2=C2OCOC2=C1 JUCQIXUOLHWYIO-UHFFFAOYSA-N 0.000 claims 1
- QWLONAKTOUSDIR-UHFFFAOYSA-N 7,8-dihydro-3h-[1,4]dioxino[2,3-e]benzimidazole Chemical group O1CCOC2=C1C=CC1=C2NC=N1 QWLONAKTOUSDIR-UHFFFAOYSA-N 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 1
- 101150017750 FGFRL1 gene Proteins 0.000 claims 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
- 102100026149 Fibroblast growth factor receptor-like 1 Human genes 0.000 claims 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000002231 Muscle Neoplasms Diseases 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 1
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 125000001118 alkylidene group Chemical group 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 125000005518 carboxamido group Chemical group 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 201000002077 muscle cancer Diseases 0.000 claims 1
- 125000001326 naphthylalkyl group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000565 sulfonamide group Chemical group 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0305088A FR2854159B1 (fr) | 2003-04-25 | 2003-04-25 | Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
| PCT/FR2004/000979 WO2004096792A2 (fr) | 2003-04-25 | 2004-04-22 | Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524668A JP2006524668A (ja) | 2006-11-02 |
| JP2006524668A5 true JP2006524668A5 (https=) | 2007-06-14 |
Family
ID=33104394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505807A Pending JP2006524668A (ja) | 2003-04-25 | 2004-04-22 | 新規なインドール誘導体、ならびに医薬物質および医薬組成物、特にｋｄｒ阻害剤としてのそれらの製造法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1633738A2 (https=) |
| JP (1) | JP2006524668A (https=) |
| FR (1) | FR2854159B1 (https=) |
| WO (1) | WO2004096792A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| US20070254877A1 (en) * | 2004-06-02 | 2007-11-01 | Takada Pharmaceutical Company Limited | Indole Derivative and Use for Treatment of Cancer |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| JP2008507518A (ja) | 2004-07-22 | 2008-03-13 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎を治療するためのチエノピリジン |
| EP1968579A1 (en) * | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP2049119A2 (en) * | 2006-06-29 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea |
| PH12012500252A1 (en) | 2009-08-07 | 2015-06-26 | Chugai Pharmaceutical Co Ltd | Aminopyrazole derivative |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| US10391081B2 (en) | 2013-12-27 | 2019-08-27 | Chugai Seiyaku Kabushiki Kaisha | FGFR gatekeeper mutant gene and drug targeting same |
| EP3312172B1 (en) | 2015-06-17 | 2020-05-06 | Chugai Seiyaku Kabushiki Kaisha | Aminopyrazole derivatives useful as src kinase inhibitors |
| WO2019126081A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Amide substituted indole compounds useful as tlr inhibitors |
| CN115052860B (zh) * | 2020-01-30 | 2024-06-21 | 艾尼莫生物科技公司 | 胶原蛋白1翻译抑制剂和其使用方法 |
| TW202302541A (zh) * | 2021-03-17 | 2023-01-16 | 美商翰森生物有限責任公司 | 含氮雜環酮、其製備方法和醫藥用途 |
| CN116332912B (zh) * | 2023-03-02 | 2025-08-19 | 广西大学 | 一种2-氨基-5-硫基吲哚类衍生物的合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| JP2001122855A (ja) * | 1999-10-27 | 2001-05-08 | Japan Tobacco Inc | インドール化合物及びその医薬用途 |
| YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| JP2004501083A (ja) * | 2000-04-18 | 2004-01-15 | アゴーロン・ファーマシューティカルズ・インコーポレイテッド | プロテインキナーゼを阻害するためのピラゾール |
| US7101884B2 (en) * | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| FR2831537B1 (fr) * | 2001-10-26 | 2008-02-29 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation |
-
2003
- 2003-04-25 FR FR0305088A patent/FR2854159B1/fr not_active Expired - Fee Related
-
2004
- 2004-04-22 EP EP04742556A patent/EP1633738A2/fr not_active Ceased
- 2004-04-22 JP JP2006505807A patent/JP2006524668A/ja active Pending
- 2004-04-22 WO PCT/FR2004/000979 patent/WO2004096792A2/fr not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006524668A5 (https=) | ||
| CN102491969B (zh) | 杂芳族喹啉化合物及其作为pde10抑制剂的用途 | |
| JP2010116411A (ja) | キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類 | |
| CN102498114A (zh) | 作为酪氨酸激酶调节剂的化合物 | |
| JP2011173915A (ja) | 新規な化合物 | |
| JP2006514110A5 (https=) | ||
| JP2006528161A (ja) | ヒスタミンのアンタゴニストとしてのピペリジンのイミダゾール誘導体 | |
| KR102304478B1 (ko) | Ras를 분해하는 이종원자고리화합물 및 이의 용도 | |
| US8946282B2 (en) | Indolin-2-one derivatives as protein kinase inhibitors | |
| CN101952258A (zh) | 作为胰岛素分泌刺激剂的喹喔啉酮衍生物、获得它们的方法及其在治疗糖尿病中的用途 | |
| JP2022519237A (ja) | Ｄｎａポリメラーゼシータ阻害剤としてのアセトアミド誘導体 | |
| CA2767064C (fr) | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) | |
| CN114007671B (zh) | 用于治疗上皮组织的慢性炎性损伤、化生、发育异常和癌症的方法和组合物 | |
| CA2754085A1 (en) | Novel hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same | |
| CA2598536A1 (en) | Oxyindole derivatives as 5ht4 receptor agonists | |
| WO2012089633A9 (fr) | Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) | |
| CN101918395A (zh) | 三唑联噁二唑衍生物 | |
| CA2504907A1 (en) | Indoles useful in the treatment of androgen-receptor related diseases | |
| DE69105135T2 (de) | Piperidyl-substituierte indole. | |
| CN106957242A (zh) | 一种希夫碱类化合物及其制备方法和制药用途 | |
| EP3297991B1 (en) | Novel amidoheteroaryl aroyl hydrazide ethynes | |
| JP4216072B2 (ja) | ドーパミンｄ２受容体及びセロトニン再取り込み部位に対する高い親和性を有する８−｛４−［３−（５−フルオロー１ｈ−インドール−３−イル）−プロピル］−ピペラジン−１−イル｝−２−メチル−４ｈ−ベンゾ［１，４］オキサジン−３−オンメシラート | |
| CN101406469B (zh) | Gal3受体拮抗剂在治疗抑郁和/或焦虑中的应用及在这种方法中有用的化合物 | |
| AU2005240733A1 (en) | Novel beta agonists, method for producing the same and their use as drugs | |
| CN101296903A (zh) | 新颖含吲哚的β-激动剂、其制备方法及其作为药物的用途 |